IMDb.com, Inc. n'assume aucune responsabilité quant au contenu ou à l'exactitude des articles de presse, des tweets ou des billets de blogue susmentionnés. Ce contenu est publié uniquement dans le but ...

Eli Lilly delivered 54% revenue growth in Q3 2025, raised full-year guidance, and remains a defensive haven amid market volatility. LLY's obesity and diabetes franchise, led by Zepbound, Mounjaro, and ...

Eli Lilly and Co (NYSE: LLY) shares are trading higher on Friday. The company plans to start selling its obesity drug through a new approach aimed at expanding access. What To Know: Eli Lilly is ...

Eli Lilly shares rose again Tuesday, their sixth increase in the past seven sessions. The drugmaker's market cap also closed at a record, $973.8 billion, as Lilly inched closer to the $1 trillion ...

Sen. Ruben Gallego (D-Ariz.) is asking for more information on Eli Lilly’s recently announced agreement with the Trump administration regarding the sale of its GLP-1 medication. In a letter to Lilly ...

*The Women’s Image Network (WIN) celebrated its 27th Annual Women’s Image Awards on Sunday, November 9, 2025, at The Fine Arts Theater in Beverly Hills. The inspirational evening, dedicated to ...

Both Eli Lilly and Novo Nordisk are denying a telehealth company’s claim of having struck partnerships with the two companies to provide direct access to their popular obesity meds. Thursday morning, ...

Eli Lilly is inking a $100 million-plus biobucks deal with Insilico Medicine in hopes of using artificial intelligence to discover new drugs. The Indianapolis Big Pharma will combine Insilico’s Pharma ...

Eli Lilly (LLY) has reached a research and licensing agreement worth up to $1.2B with SanegeneBio to develop and commercialize RNAi therapeutics for metabolic diseases, the Boston, Massachusetts-based ...

Weight loss drugs generated about $10 billion for Lilly in the most recent quarter. One particular hurdle for some patients, however, has been the price of these products. Medicare so far hasn't ...

Early results showed that patients lost up to 20.1% of their body weight. Eli Lilly's next generation of weight loss drugs appear to show promise, possibly leading to even faster weight loss and added ...

Eli Lilly has pulled out of the central nervous system (CNS)-focused portion of a $960 million biobucks deal centered on Rigel Pharmaceuticals’ receptor-interacting serine/threonine-protein kinase 1 ...